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DOI: 10.1039/c0sm01539cPolylactide (PLA) and its copolymers are one type of hydrophobic aliphatic polyester based on
hydroxyalkanoic acids. They possess exceptional qualities: biocompatibility; FDA approval for clinical
use; biodegradability by enzyme and hydrolysis under physiological conditions; low immunogenicity;
and good mechanical properties. These critical properties have facilitated their value as sutures,
implants for bone fixation, drug delivery vehicles, and tissue engineering scaffolds in pharmaceutical
and biomedical applications. However, the hydrophobicity of PLA and its copolymers remains
concerns for further biological and biomedical applications. One promising approach is to design and
synthesize well-controlled PLA-based amphiphilic block copolymers (ABPs); typical hydrophilic
copolymers include poly(meth)acrylates, poly(ethylene glycol), polypeptides, polysaccharides, and
polyurethanes. This review summarizes recent advances in the synthesis and self-assembly of
PLA-containing ABPs and their bio-related applications including drug delivery and imaging
platforms of self-assembled nanoparticles, and tissue engineering of crosslinked hydrogels.1. Introduction
Hydrophobic aliphatic polyesters based on hydroxyalkanoic
acids, such as polylactide (PLA), polycaprolactone (PCL), and
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5096 | Soft Matter, 2011, 7, 5096–5108copolymers are biocompatible, FDA-approved for a clinical use,
and biodegradable by enzyme and hydrolysis under physiolog-
ical conditions. They also have low immunogenicity and good
mechanical properties. These unique properties have facilitated
their use in pharmaceutical and biomedical applications as
sutures, implants for bone fixation, drug delivery vehicles, and
tissue engineering scaffolds.1–4 PLA and its copolymers are
generally synthesized by ring opening polymerization (ROP) of
LA and copolymerization with other cyclic monomers, initiated
with hydroxyl- and amine-functionalized initiators. Examples of
the typical cyclic monomers include mainly GA for PLGA,5–10
CL for P(LA-co-CL),11 a cyclic carbonate monomer
for P(LA-co-carbonate),12 dipropargyl glycolide (DPGA) for
P(LA-co-DPGA),13 and allyl glycidyl ether (AGE) for
PLA-b-PAGE.14,15 Recently, the synthesis of functional
polyesters including PLA has been reviewed.16,17 PLA exists as
three types of stereoisomers; optically active poly(L-()-S-lac-
tide) (PLLA) and poly(D-(+)-R-lactide) (PDLA), and racemic
PDLLA. Stereoisomeric mixtures of PLLA/PDLA form stereo-
complexes through physical association of PLLA and PDLA
chains with distinctive physical and chemical stability and
enhanced mechanical strength.18
For successful biological and biomedical applications of PLA
and its copolymers, one serious challenge is associated with their
hydrophobicity. For hydrophobic drug delivery applications, as
an example, the hydrophobicity of PLA and its copolymers
enhances the uptake of drug-loaded nanoparticles (NPs) through
mononuclear phagocyte system (MPS), resulting in their short
residence time in circulation. This consequently causes a decrease















































View Onlinelong circulation of hydrophobic PLA-based NPs in the blood is
to coat their surface with hydrophilic polymers. This approach
has been facilitated by preparation of well-controlled PLA-
containing amphiphilic block copolymers (ABPs) for drug
delivery applications. These ABPs self-assemble in water toward
the formation of core/shell micellar NPs; a hydrophobic core is
capable of carrying a variety of hydrophobic therapeutic agents
and hydrophilic coronas ensure water-solubility and biocom-
patibility of the NPs.19 In addition, PLA-based ABPs have been
explored for the development of other biomaterials, including
crosslinked hydrogels as tissue engineering scaffolds and self-
assembled metal hybrid nanomaterials as imaging platforms.
Another challenge is to engineer PLA-based ABPs capable of
bioconjugation with ligand biomolecules for targeting specific
cells as well as promoting biocompatibility with living cells. This
has been achieved by designing functional PLA-based ABPs. The
functional groups that have been exploited include carboxylic
acid (–COOH), amino (–NH2), and hydroxyl (–OH) groups,
which are utilized for bioconjugation with targeting biomolecules
to achieve active targeting of specific cells.
This review describes recent advances in the synthesis and
biomedical application of PLA-based biomaterials. Since these
materials are built with ABPs through self-assembly, this review
begins with the preparation and self-assembly of PLA-based
ABPs using a hydrophilic block; typical hydrophilic copolymers
include poly(meth)acrylates, poly(ethylene glycol) (PEG), poly-
peptides, polysaccharides, and polyurethanes. These copolymers
are either naturally occurring or mainly synthesized by radical,
ring opening, or condensation polymerization methods. Further,
this review summarizes biological and biomedical applications of
these PLA-based ABPs, including biological evaluations—cyto-
toxicity and viability, drug delivery and imaging platforms of
self-assembled NPs, and tissue engineering of crosslinked
hydrogels.2. Preparation and self-assembly of PLA-based
amphiphilic block copolymers
A variety of methods to synthesize well-defined PLA-based
ABPs with hydrophilic polymers have been explored. Typical
examples of hydrophilic polymers include poly(meth)acrylates,
PEG, polypeptides, polysaccharides, and polyurethanes. These
ABPs self-assemble to form micellar core/shell NPs.Fig. 1 Chemical structure of hydrophilic (meth)acrylate mo
This journal is ª The Royal Society of Chemistry 20112.1. Hydrophilic poly(meth)acrylates
A general method to prepare PLA-based ABPs comprising
hydrophilic poly(meth)acrylates involves controlled radical
polymerization (CRP)20,21 of hydrophilic (or water-soluble)
monomers from hydrophobic PLA. In contrast to conventional
free radical polymerization, CRP methods adopt the mechanism
based on a rapid dynamic equilibration between a minute
amount of growing radicals and a large majority of dormant
species. Consequently, all polymeric chains grow simultaneously,
leading to uniform distribution of molecular weights. These
methods enable the synthesis of well-defined (co)polymers with
narrow molecular weight distribution (Mw/Mn < 1.5), various
chain architectures (block, gradient, graft, hyperbranched, and
star), and facile functionalities. Examples of successful CRP
methods include atom transfer radical polymerization
(ATRP)22,23 and reversible addition-fragmentation chain transfer
(RAFT) polymerization.24,25 Fig. 1 shows the structures of
hydrophilic monomers examined for the synthesis of PLA-based
ABPs in the literature.
The ATRP has been extensively explored for chain extension
of PLA with hydrophilic polymers because of its facile applica-
bility to the synthesis of well-controlled PLA-containing ABPs.
A prototype approach involves three synthetic steps (Fig. 2a): (1)
ROP of LA to form PLA–OH, (2) conversion of PLA–OH to the
corresponding PLA–Br (ATRP macroinitiator), and (3) ATRP
of hydrophilic monomers in the presence of PLA–Br. An
example includes the synthesis of PLA-b-poly(2-meth-
acryloyloxyethyl phosphorylcholine) (PMPC). PMPC is known
to suppress protein adsorption and platelet adhesion and thus
PMPC-based materials have been developed for biomedical
applications.26,27 The first step was the synthesis of PLA–OH by
the ROP of LA initiated by benzoyl alcohol. The second step was
the synthesis of PLA–Br by reaction of PLA–OH with 2-bromo-
2-methylpropionyl bromide (BMPB). The last step was the
ATRP of MPC in the presence of PLA–Br, mediated with
CuBr(I)/2,20-bipyridine (bpy) catalysts. The structure of the
resulting PLA-b-PMPC was characterized with composition
by NMR and FT-IR spectroscopy, molecular weight by
gel permeation chromatography (GPC), and critical micellar
concentration (CMC) by fluorescence spectroscopy. Then, the
resulting PLA-b-PMPC self-assembled in a mixed solvent of
EtOH/DMSO using a solvent evaporation method to form stable
core/shell NPs comprising PLA core surrounded with PMPC
coronas. Their particle size was determined by dynamic lightnomers examined for the synthesis of PLA-based ABPs.
Soft Matter, 2011, 7, 5096–5108 | 5097
















































View Onlinescattering technique to be 100–160 nm in diameter. Their diam-
eter increased from 118 to 156 nm as the degree of polymeriza-
tion of PMPC block increased from 67 to 150. Their
biological properties were tested with cytotoxicity to
be >85%, suggesting they are biocompatible up to the concen-
tration of 1 mg mL1.28 PLA-b-poly(N,N-dimethylaminoethyl
methacrylate) (PDMAEMA) was synthesized for self-assembly,
encapsulation, and pH-responsive release of dipyridamole,
a hydrophobic drug.29 A pair of PLLA-b-PDMAEMA (L-stereo
form) and PDLA-b-PDMAEMA (D-stereo form) was investi-
gated for stereocomplex formation in water. The resulting
stereocomplexes exhibited diffraction patterns assigned to ster-
eocomplex crystallites; their melting point was 65 C higher than
that of individual copolymers.30 Similar approach was also
adopted to synthesize PCL-based ABPs. An example includes
PEO-b-PCL-b-PDMAEMA for gene-delivery applications.31
However, this prototype approach requires the conversion of
PLA–OH to PLA–Br ATRP macroinitiator.
Another approach involves the use of 2-hydroxyethyl-2-bro-
moisobutyrate (HO-EBiB) as an initiator for both ROP and
ATRP: its OH group for the ROP of LA and its bromo group for
the ATRP of hydrophilic monomers (Fig. 2b). This approach can
be achieved in a rapid one-pot route without purification of
PLA–Br intermediates or in a two-pot route.32 Well-controlled
PLA-b-poly(2-hydroxyethyl methacrylate) (PHEMA) with
Mw/Mn ¼ 1.2–1.3 was synthesized and characterized using GPC
and 1H-NMR.33 PLA-b-poly(oligo(ethylene glycol) methacry-
late) functionalized with pendent sugar residues was prepared to
investigate the molecular recognition of lectin through carbo-
hydrate–protein specific interactions.34 PLA-b-poly(glycerol
monomethacrylate) (PGlyMA) was prepared.35,36 Several reports5098 | Soft Matter, 2011, 7, 5096–5108describe the successful ATRP of GlyMA in aqueous or protic
solvents.35,37 For the synthesis of PLA-b-PGlyMA, however,
PLA was not dissolved in protic media; consequently, PGlyMA
block was generated by the hydrolysis of pendent protected
groups from the parent polymers, such as silyl groups from
poly(2,3-bistrimethylsilyloxypropyl methacrylate) (P(GlyMA–
TMS))38 and acetal groups from poly(2-phenyl-1,3-dioxan-5-
ylmethacrylate) (P(GlyMA–PhDO).39
A zwitterionic block copolymer based on PLGA was
synthesized by ATRP of 2-tert-butoxy-N-(2-(methacryloyloxy)-
ethyl)-N,N-dimethyl-2-oxoethanaminium (CB-tBu-MA) in the
presence of 2-aminoethyl-2-bromoisobutyrate, followed by
a carbodiimide coupling reaction with PLGA. The resulting
PLGA-b-P(CB-tBu-MA) was hydrolyzed to convert tert-butyl
ester groups to the corresponding carboxylic acid groups in the
presence of trifluoroacetic acid, yielding PLGA-b-P(CB-MA)
zwitterionic block copolymers. This approach centers on the
design of CB side chain having one carboxylic acid that can be
used for conjugation with amine-containing biomolecules. Since
each carboxylic acid in pendent CB is paired with one cationic
quaternary amine as a zwitterionic unit, this pairing exhibited
improvement of nonspecific protein absorption (Fig. 3). PLGA–
P(CB-MA) self-assembled in the presence of docetaxel, yielding 1
wt% docetaxel-encapsulated NPs with a diameter of 139 nm. The
drug release experiments indicate the sustained releasing profile
of docetaxel over 96 h for both P(CB-MA)-modified and
unmodified NPs. In order to investigate cell uptake, these NPs
were then modified with galactose to form galactose-modified
NPs. A green fluorescent dye called NBD (N-(7-nitro-benz-2-
oxa-1,3-dizaol-4-yl) was encapsulated as a fluorescent label.
NBD-loaded PLGA–P(CB-MA) NPs were incubated withThis journal is ª The Royal Society of Chemistry 2011
Fig. 3 Synthesis of PLGA–P(CB-MA) copolymers, formation of PLGA–PCB NPs encapsulated with docetaxel, and modification of NPs with tar-
















































View OnlineHepG2 cells. It was found that galactose-modified NPs were
bound to cells, producing strong fluorescence, while NPs without
immobilized ligands resulted in nonspecific targeting, showing
low cell binding ability.40
RAFT polymerization has also been explored for the prepa-
ration of PLA-based ABPs; however, the selection of functional
RAFT agents is somewhat limited. A typical approach is the use
of OH-functionalized RAFT agents as initiators for
both ROP and RAFT polymerization (Fig. 4). 2-[N-
(2-Hydroxyethyl)carbamoyl]prop-2-yl dithiobenzoate (HECPD)
was synthesized and utilized for the synthesis of thermo-
responsive PLA-b-poly(N-isopropylacrylamide-co-N,N-
dimethylacrylamide) (P(NIPAM-co-DMAm)). Terminal dithio
groups were converted to the corresponding thiols by aminolysis,
which were used for conjugation with fluorescent dyes. It was
observed that intercellular uptake of thermoresponsive micelles
formed from P(NIPAM-co-DMAm) was significantly increased
at temperatures above the low critical solution temperature
(LCST).41,42 Similarly, 2-(benylsulfanylthiocarbonyl-
sulfanyl)ethanol (BSTSE) was utilized to prepare PLGA-b-
P(oligo(ethylene oxide) monomethyl ether methacrylate)
(POEOMA). The self-assembled micelles were characterized
using dynamic light scattering and cytotoxicity of 3T3 fibroblastThis journal is ª The Royal Society of Chemistry 2011cells.43 Recently, a new route towards the synthesis of functional
PLA-b-poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA)
was proposed. The synthesis relies on a combination of ROP of
LA and conversion into a chain transfer agent for the RAFT
polymerization of pentafluorophenyl methacrylate (PFMA).
4-Cyano-4-((thiobenzoyl)sulfanyl) pentatonic acid (CTA) first
reacted with the OH group of PLA to form PLA-functionalized
macro-RAFT agent. This agent was then used to mediate the
RAFT polymerization of PFMA for PLA-b-PPFMA prepara-
tion. The pendent pentafluoro groups were then substituted with
Oregon Green 488, a fluorescent dye and hydroxypropylamine,
resulting in a fluorescently labeled PLA-b-PHPMA for potential
drug delivery.44
In addition, nitroxide-medicated radical polymerization45 and
conventional free radical polymerization46,47 have been explored
for the preparation of PLA-based ABPs.2.2. PEG
Poly(ethylene glycol) (PEG) is the most commonly applied
nonionic, hydrophilic polymer. PEG is FDA-approved for
clinical use; it has prolonged blood circulation and diminished
reticuloendothelial system (RES) uptake.48 Thus, PEGylationSoft Matter, 2011, 7, 5096–5108 | 5099
Fig. 4 Synthesis of PLA-b-P(NIPAM-co-DMAm) (a) and conversion of thermoresponsive polymer termini and formation of polymeric micelles (b).42















































View Onlinehas been extensively employed as an effective method of choice in
the development of biocompatible materials for many biological
and biomedical applications.49 Recently, the pros and cons for
PEGylation for drug delivery have been reviewed.50
PEG has been used to modify hydrophobic PLA, typically as
initiating species for the ROP of LA to prepare PEG-containing
PLA ABPs. Typical examples include self-assembled NPs of
methoxy-capped PEG (mPEG)-b-PLA,51 mPEG-b-poly(hexyl-
substituted LA),52 PLA-b-PEG-b-PLA,53 PEG/star-b-PLA,54
PLGA-b-PEG,55 and H40 hyperbranched polyester-modified
PLA-b-PEG,56 as well as vesicle of mPEG44-b-PLAx (note that
44 and x are the degree of polymerization).57 The modification of
PLA with conventional PEG is relatively facile, compared to
other methods. However, one of its drawbacks involves the lack
of functional groups in the resulting PEG-b-PLA that can be
used for further bioconjugation. Several approaches have been
proposed to synthesize functional PEG-b-PLA. A triblock
copolymer consisting of mPEG, pendent propargyl-containingFig. 5 A schematic illustration (a) and a SEM image (b) of paclitaxel-loade
PNAS.
5100 | Soft Matter, 2011, 7, 5096–5108polymer as a middle block, and PLA was prepared and self-
assembled to formmicellar NPs. The propargyl groups were used
for conjugation with azido-functionalized hemoglobin molecules
through click-type Cu(I)-mediated Huisgen 1,3-dipolar cycload-
dition as artificial oxygen carriers.58 Fig. 5 illustrates the
synthesis of COOH-functionalized PEG-b-PLGA by coupling
reaction of PLGA (–COOH group) with NH2–PEG–COOH
(–NH2 group). The resultant ABPs were self-assembled in the
presence of paclitaxel through nanoprecipitation to form pacli-
taxel-loaded NPs. The terminal –COOH groups at the end of
PEG chains of self-assembled NPs were bioconjugated with
aptamer (nucleic acids as cancer therapeutics) for targeted cancer
chemotherapy.592.3. Polypeptides
Synthetic polypeptides based on a-amino acids, poly(a-amino
acids), are biocompatible and biodegradable. As shown ind NP-aptamer bioconjugates for cancer chemotherapy.59 Copyright 2006















































View OnlineFig. 6a, several poly(a-amino acids) possess pendent functional
groups, including carboxylic acid (–COOH) for aspartic acid and
glutamic acid, thiol (–SH) for cysteine, and amine (–NH2) for
lysine. These functional groups are further utilized for
bioconjugation and shell-crosslinking. These unique properties
have promoted the use of functional poly(a-amino acids) as
hydrophilic polymers to coat hydrophobic PLA NPs. Two
general methods have been proposed for the preparation of
unique PLA-based poly(a-amino acids) ABPs. Both methods
require the protective group chemistry of a-amino acids to avoid
the side reactions of –NH2 and –COOH groups during
polymerization.
A facile method involves the ROP of a-amino acid N-car-
boxyanhydrides (NCAs) from NH2-terminated PLA (NH2–
PLA). Fig. 6b shows the a-amino acid NCAs reported in the
literature. This method generally includes three steps; (1)
synthesis of NH2–PLA, (2) ROP of a-amino acid NCA, and (3)
removal of NCA groups through hydrolysis or catalytic hydro-
genation. The preparation of PLA-b-poly(aspartic acid) (PLA-b-
PAsp) is illustrated in Fig. 7.60 First, BOC–NH2–PLA was
synthesized by the ROP of LA in the presence of BOC–amino-
ethanol, which was synthesized by the reaction of aminoethanolFig. 6 Examples of a-amino acids having pendent functional groups (a)
and a-amino acid N-carboxyanhydrides (b).
Fig. 7 An illustration of synthesis of PLA-b-PAsp block copolymer.60
Copyright 2004 Wiley InterScience.
This journal is ª The Royal Society of Chemistry 2011with (BOC)2O. The BOC group of BOC–NH2–PLA was then
removed by hydrolysis for the formation of NH2–PLA.
61 Next,
the ROP of b-benzyl-L-aspartate NCA (BLA–NCA) in
the presence of NH2–PLA as the macroinitiator yielded
PLA-b-P(Asp NCA), a precursor of PLA-b-PAsp by hydrolysis.
The resulting PLA-b-PAsp ABP formed core/shell type
biodegradable micelles with a diameter of <50 nm.62
For the preparation of mPEG-b-PLA-b-poly(L-glutamic acid)
(PGlu) triblock copolymer, NH2-terminated mPEG-b-PLA was
prepared by ROP of LA in the presence of mPEG, reaction with
tert-butyloxycarbonyl-L-phenylalanine (Phe-BOC), and removal
of BOC groups. The ROP of g-benzyl-L-glutamate NCA
(BLG–NCA) in the presence of NH2-terminated mPEG-b-PLA
then yielded mPEG-b-PLA-b-P(BLG–NCA), a precursor of
mPEG-b-PLA-b-PGlu by catalytic hydrogenation.63 Similar
approach has resulted in PLA-b-PGlu-b-PLA triblock copol-
ymer. The pendent COOH groups of the triblock copolymer
were further modified with RGD peptide for targeted
drug delivery applications.64 The synthesis of mPEG-b-PLA-b-
poly(L-lysine)65 and PLA-b-poly(L-cysteine)66 was also reported.
The coupling reaction has been explored. An example includes
the synthesis of PLGA-b-PGlu by the carbodiimide coupling
reaction ofNH2-terminatedPGluwithCOOH-terminated PLGA
in the presence of 1-ethyl-(3-dimethylaminopropyl) carbodiimide
(EDC) in water. The COOH-terminated PLGA was prepared by
the reaction of OH-terminated PLGA with succinic anhydride.
These ABPs exhibited pH responsiveness; their morphologies
varied fromdisordered forms tomicelles, and further to vesicles as
pH increased from 4 to 9.67 PLA-b-PGlu was prepared by
coupling reaction of OH-terminated PLA with NH2-terminated
PGlu in the presence of N,N0-carbonyldiimidazole (CDI). The
resulting ABPs self-assembled to form micellar NPs. Their
terminal COOH groups reacted with galactosamine, yielding
galactosylated NPs.68 In addition, grafting of PLA onto
poly(hydroxyethyl aspartamide) copolymers has been reported.692.4. Polysaccharides
Polysaccharides are naturally occurring biopolymers that are
abundant in nature, intrinsically biodegradable and renewable.
Ethyl cellulose,70 cellulose,71 cellulose fiber,72 and hydroxypropyl
cellulose73 were grafted with PLA. PLA-grafted pullulan,74
amylose,75 and dextran76 were prepared through three steps:
silylation of hydroxyl groups, ROP of LA initiated with
remaining hydroxyl groups, and silylether deprotection. These
PLA-grafted polysaccharides exhibit amphiphilic characteristics.
Thus, they were useful as biodegradable films and fibers as well as
enabled stabilizing both direct and inverse miniemulsions.77–79 In
addition, PLA-grafted dextran-based microspheres were
prepared by solvent evaporation/extraction method in water-in-
oil-in-water (W/O/W) emulsion. The release behavior of bovine
serum albumin80 and lysozyme81 from microspheres was
examined.
Similarly, hyaluronic acid (HA) was grafted with PLA and
PEG, yielding amphiphilic PLA-g-HA-g-PEG. Their self-
assembly toward micelle formation as well as morphology and
cytotoxicity of drug-loaded micelles were examined for targeted
release of anticancer therapeutics.82 Recently, the synthesis of















































View Online2.5. Polyurethanes with hydrophilic segments
Polyurethanes are well-known synthetic polymers prepared by
polyaddition through building blocks of urethane linkages. They
are mainly used for industrial materials because they are tough
and resistant to solvents and hydrolytic degradation. Several
papers have reported the development of biodegradable
PLA-containing polyurethanes as useful biomaterials for tissue
engineering84 and drug delivery.85 Multiblock poly(ether ester
polyurethane) comprising PLA, PEG, and poly(propylene oxide)
segments was synthesized. Their structures were characterized
with composition using NMR and IR spectroscopy and molec-
ular weight using GPC. These ABPs self-assembled to form
micellar NPs having PEG coronas. A fluorescent technique
with 1,6-diphenyl-1,3,5-hexatriene (DPH) was employed to
determine the CMC of these ABPs. These polymers exhibited
thermo-reversible sol–gel transition behavior at critical
gelation concentrations ranging from 7 to 9 wt%.84 Pendent
COOH-containing polyurethane comprising PLA and PEG was
synthesized to form micellar NPs through self-assembly.853. Bio-related applications of PLA-based
amphiphilic block copolymers
3.1. Biological evaluations—cytotoxicity
PLA-based ABPs described in Section 2 are composed of PLA
(and its copolymers) and hydrophilic polymer. These individual
building block polymers are known to be non-toxic and
biocompatible. A question is if the PLA-based copolymers are
still non-toxic. PLA-b-PHPMA ABPs was tested for cytotoxicity
using a MTT assay (a standard colorimetric assay for the eval-
uation of cell viability). The cell viability was evaluated to be
close to 100% over 72 h, indicating that PLA-b-HPMA is
nontoxic to cells up to a concentration of 3 mg mL1.44
A PLA-based thermoresponsive ABP was also evaluated to be
non-cytotoxic.423.2. Self-assembled nanoparticles for drug delivery
Polymeric micelles as drug delivery systems (DDS) offer many
advantages.86,87 These advantages include (1) colloidal stability
with low CMC, (2) tunable sizes with narrow size distribution,
(3) ability to preserve the activities of drugs during circulation inFig. 8 In vitro release of paclitaxel from NPs of PLA-b-PEG in PBS (pH 7.4
rat plasma (B).90 Copyright 2010 Elsevier.
5102 | Soft Matter, 2011, 7, 5096–5108blood, (4) high physical loading efficiency of drugs, (5)
bioconjugation for active targeting to specific diseased cells, and
(6) controllable release of drugs upon external stimuli and
degradation.88 A broad variety of self-assembled NPs of
PLA-based ABPs has been explored as effective delivery carriers
of encapsulated biomolecules. Examples include plasmid–
DNA89 and carboxyfluorescein (a fluorescent dye as model
drug),43 as well as hydrophobic anticancer drugs such as mainly
paclitaxel,40,59,68,90 CPT-11,91 doxorubicin (Dox),92,93 and glicla-
zide (a second-generation hypoglycemic sulfonylurea agent).85
For DNA delivery, PLA-b-PDMAEMA was prepared and
the PDMAEMA block was protonated. The self-assembled
core/shell NPs consisted of a PLA core (loading drugs)
surrounded with protonated PDMAEMA coronas. The cationic
PDMAEMA coronas facilitated DNA loading through ionic
interactions with anionic phosphate groups of DNA molecules.
For drug delivery, hydrophobic drugs are loaded inside core/shell
NPs of PLA-based ABPs. The drug loading level (amount of
drugs loaded in NPs) and encapsulation efficiency (ratio of the
amount of loaded drugs to feed drugs) are characterized using
UV/vis spectroscopy for UV-active drugs and HPLC for pacli-
taxel. One of the important formulation parameters that signif-
icantly influence the drug loading level appears to be the feeding
level of drugs. For example, paclitaxel-loaded thermo- and pH-
dual-responsive NPs of PLA-b-P(NIPAM-co-acrylic acid) had
a diameter of 135 nm. The paclitaxel loading increased from 3 to
30% with an increasing amount of feeding paclitaxel from 5 to
50% based on copolymers.94 In vitro release kinetics of paclitaxel
from PLA-based NPs has been explored. Several reports have
shown that more than three days are required for cumulative
release of 80% paclitaxel at pH ¼ 4.0 (Fig. 8).90 Such a slow
release may be attributed to delayed diffusion through the
hydrophobic PLA core due to both hydrophobic interactions as
well as the slow hydrolysis of the ester linkages of the PLA
backbones. Introducing pH-responsive block copolymers into
PLA-based NPs enhances the cumulative release rate of pacli-
taxel; in this case, up to 80% of paclitaxel is released from the
mixed micelles within 5 h upon degradation at pH ¼ 6.4.93
Dox, an anticancer drug, was covalently conjugated to
mPEG-b-P(LA-co-dihydroxymethylpropylene carbonate, DHP)
via either carbamate or acid-labile hydrazone linkage. The
OH groups of DHP units were activated with 4-nitrophenyl
chloroformate and then reacted with amino groups of Dox.and 4.0) (A) and in the mixture medium (1 : 1 v/v) of PBS (pH ¼ 7.4) and















































View OnlineThe resultant mPEG-b-P(LA-DHP)/Dox co-assembled with
folic acid (FA)-conjugated mPEG-b-P(LA-co-DHP)/FA. The
resulting multifunctional mixed micelles exhibited pH-dependent
release behavior: the release of Dox upon cleavage of carbamate
and hydrazone bonds was enhanced in acidic pH.95
Cellular uptake has been studied using laser confocal fluores-
cence microscopy (LCFM). For the studies, NPs of PLA-based
ABPs were encapsulated with fluorescence dyes and incubated
with living cells such as HeLa and 3T3 cells. LCFM results
suggest that these NPs are uniformly distributed inside cells.
Active targeting is a promising approach toward increasing local
accumulation of NPs in diseased tissue.96,97 This approach
requires the design and preparation of functional NPs that are
further conjugated with targeting biomolecules to specific cells
through specific receptor–ligand or antigen–antibody interac-
tions. These biomolecules that have been attached to PLA-based
NPs include folate,56,98 RGD,64 peptide,90,93 carbohydrate
(galactosamine),68 and aptamer.59
Tumor targeting ability of peptide (CRKRLDRN)-conju-
gated, pH-responsive mixed micellar NPs was examined using
the noninvasive and live optical imaging system (Fig. 9). The NPsFig. 9 In vivo and ex vivo biodistribution of peptide-conjugated, pH-resp
a control without peptide conjugation; in vivo fluorescence image of MDA-M
in vivo tumor targeting ability of both NPs recorded as total photon counts per
post-injection (n ¼ 3) (b), and an ex vivo fluorescence image of dissected organ
Chemical Society.
This journal is ª The Royal Society of Chemistry 2011containing 1 mg kg1 of TRIRC (a fluorescent dye) were
administered intravenously into MDA-MB21 human breast
tumor-bearing mice. Compared to the control non-conjugated
with the targeting peptide, total photon counts (quantified for
fluorescent signals) at targeted tumor tissues were larger for
peptide-conjugated NPs. In addition, ex vivo fluorescence images
of excised organs show tumor-targeting ability of peptide-
conjugated NPs.933.3. Diagnostics/imaging platforms
Colloidal inorganic nanocrystals have unique physical and
optical properties attributed to nanoscale phenomena. These
nanocrystals, typically including magnetic NPs (MNPs) and
quantum dots (QDs), have proved to be useful as building block
for the development of nanomaterials and biomaterials in
nanoscience and biotechnology. MNPs have great potential for
magnetic resonance imaging (MRI) that is a non-invasive
imaging method utilized in clinical medicine. This MRI method
is based on the relaxation of protons in tissues; upon accumu-
lation in tissues, magnetic NPs enhance proton relaxation ofonsive micelles containing TRIRC (a fluorescent dye), compared with
A-231 tumor-bearing mice injected with both NPs (a), quantification of
centimetre squared per steradian (p s1 cm2 sr1) per each tumor at 1 day
s after 24 h post-injection of both NPs (c).93 Copyright in 2010 American















































View Onlinespecific tissues when compared with the surrounding tissues,
serving as a MR contrast agent.99–101 CdX (X ¼ Se, S, and Te)
QDs have unique photoluminescence properties such as narrow
and size-dependent emission spectra, multicolor excitation, and
excellent photostability against photobreaching. Due to these
distinct advantages, they are useful as biological labeling in
biological applications.102–105
Self-assembled NPs of PLA-based ABPs have been loaded
with MNPs and QDs. This requires the modification of metal
nanocrystal surfaces with hydrophobic ligands, facilitating their
encapsulation in the hydrophobic PLA-based inner core. A
typical example includes COOH-terminated PLA-b-PEG that
self-assembled in the presence of hydrophobic MNPs and Dox,
resulting in Dox-loaded, MNP-embedded core/shell NPs. These
NPs were then functionalized with therapeutic antibodies tar-
geting to tumors for a MRI probe (Fig. 10). After internalization
into cells, Dox was released upon the collapse of micellar
aggregates and the viability of cancer cells was monitored using
the MRI.106 Other examples include self-assembled NPs of well-
controlled PLA-b-POEOMA functionalized with folate107 and
a mixture of maleimide-terminated PEG-b-PLA and methoxy-
terminated PEG-b-PLA.108 CdSe/ZnS core/shell QDs were
encapsulated in PEG-b-PLA NPs for biomedical imaging probes
and drug delivery carriers.109
Several methods that enable the encapsulation of metal
nanocrystals in PLA homopolymers have been explored, typi-
cally including heterogeneous polymerization in miniemulsion110
and supercritical carbon dioxide,111 and precipitation–solvent
evaporation.112,113 In addition, other methods to prepare a PLA
layer on single crystals have been explored, including surface
modification of nanocrystals with thiol-terminated PLA114 and
surface-initiated ROP of LA.66
3.4. Crosslinked hydrogels for tissue engineering
Hydrogels are a three-dimensional network crosslinked with
hydrophilic polymers. They have biocompatibility, high water
content, tunable chemical and physical structure, and enhanced
mechanical properties. Due to these unique properties, hydrogels
have a great potential in the development of useful biomaterials
for biological and biomedical applications.115–117 Effective
hydrogels have been extensively explored for regenerativeFig. 10 Fabrication of a MRI probe from core/shell NPs of COOH-
functionalized PLA-b-PEO consisting of PLA inner core embedded with
MNPs and doxorubicin and a shell functionalized with targeting thera-
peutic antibodies to tumor.106 Copyright 2007 Wiley InterScience.
5104 | Soft Matter, 2011, 7, 5096–5108medicine (or tissue engineering) and drug delivery,118–121 as well
as for the development of a variety of advanced biomaterials
including biosensors and detection,122–124 microfluidic bio-
materials,125–127 drug conjugates,128 catalysis,129 and photonic
crystals.130,131 Both synthetic and biopolymer-based hydrogels
are generally prepared via two methods: chemical crosslinking
and physical crosslinking.83,132 PLA as well as PLA-based ABPs
have been utilized for the development of well-defined biode-
gradable hydrogels by both chemical and physical crosslinking
methods. Typical methods include temperature-induced sol–gel
transition, stereocomplexation, ionic interaction, and photo-
induced crosslinking polymerization.
Temperature-induced sol–gel transition of in situ thermogel-
ling polymers is attractive for tissue engineering and drug
delivery applications. This is because an aqueous solution of in
situ gel-forming polymers is in a low viscous sol phase at room
temperature or lower, while it becomes a semisolid or gel with an
increasing temperature.133–135 ABPs comprising PEG and PLA
(or PCL) enabled in situ formation of crosslinked hydrogels in
water (>20 wt%).136 8-Arm PEG-b-PLLA conjugated with
cholesterol self-assembled to form temperature-induced hydro-
gels as an injectable scaffold for tissue engineering.137 A multi-
block copolymer of alternating PEG and PLA blocks was
synthesized by polycondensation of PEG with a,u-dicarboxylic
acid terminated PLA, which was prepared by the reaction of diol
terminated PLA with succinic anhydride. This multiblock
copolymer self-assembled to form micelles with a diameter of
20 nm in water at low temperature; as temperature increased,
these micelles were aggregated to a larger size. The key param-
eters that affect sol–gel transition temperature and gel window
are molecular weight and composition of block copolymers.138
Similar approach was applied for the synthesis of thermosensi-
tive PCL-based multiblock copolymers.139 A pH- and thermo-
sensitive triblock copolymer of P(CL-co-LA)-b-PEG-b-P(CL-co-
LA) terminated with sulfamethazine end groups was synthesized
by the ring opening copolymerization of CL and LA in the
presence of PEG as a ROP initiator. This copolymer exhibited
gelling behavior in response to pH and temperature.140
Stereocomplexation has been explored to synthesize various
types of PLA-based, physically crosslinked hydrogels in water. A
mixture of linear PLLA-b-PEG and PDLA-b-PEG formed
physically crosslinked hydrogels through stereocomplexation of
PLLA and PDLA blocks. Mechanical properties (storage and
loss moduli) increased over the mixing time, indicating the
formation of PLA-based stereocomplexed hydrogels.141 Similar
approach was utilized for the synthesis of physical hydrogels
from stereocomplex of (PLLA)8-b-PEG and (PDLA)8-b-PEG
star block polymers.142 Dextran was modified with PLLA and
PDLA and the mixture of dextran-g-PLLA and dextran-g-
PDLA formed hydrogels143,144 and nanogels with a diameter of
70 nm145 in water. Control of the degree of polymerization and
substitution of oligo-LA are key parameters that can affect the
mechanical properties of hydrogels. Further, microspheres of
dextran-g-HEMA prepared by chemical crosslinking were
modified with either PLLA or PDLA, yielding PLLA- or PDLA-
tethered microspheres. Both microspheres formed macroscopic
hydrogels through stereocomplexation (Fig. 11).146
Ionic interaction has been utilized to prepare biodegradable
colloidal gels for moldable tissue engineering scaffolds. For theThis journal is ª The Royal Society of Chemistry 2011
Fig. 11 Schematic representation of self-assembling hydrogels of PLLA-
















































View Onlineapproach, oppositely charged colloidal NPs were first prepared
by the solvent evaporation method of mixtures of PLGA
with ionic polymers: polyvinylamine for cationic NPs and
poly(ethylene-co-maleic acid) for anionic NPs. The oppositely
charged NPs were then mixed to form colloidal network gels by
ionic interaction. They exhibited pseudoplastic rheology
behavior, which was utilized to construct differently shaped
tissue scaffolds. The cytotoxicity study indicated that these
colloidal gels were compatible with human umbilical cord matrix
stem cells (HUCMSCs), suggesting the potential for effective
tissue scaffolds (Fig. 12).147
Photo-induced crosslinking polymerization is a chemical
crosslinking method that allows for the synthesis of covalentlyFig. 12 Different shapes of scaffolds made from 20 wt% colloidal gels
that are prepared by oppositely charged PLGA NPs (a and b), gels with
sufficient cohesiveness to be handled by a 20 gauge needle (c), and human
umbilical cord matrix stem cells cultured on colloidal gels (d).147
Copyright 2008 Wiley InterScience.
This journal is ª The Royal Society of Chemistry 2011crosslinked PLA-containing hydrogels. An approach involves
the copolymerization of polymerizable-bearing species with LA.
An example includes the synthesis of a copolymer consisting of
PLA, PEG, and polyfumarate (containing backbone double
bonds).148 The general approach involves the modification of
PLA-based ABPs with photo-polymerizable groups, yielding
corresponding dimethacrylates. One way is that the dimetha-
crylate derivatives of PLA-based ABPs are physically gelled in
aqueous solution through either sol–gel transition or stereo-
complexation. The resulting physical gels are then locked
by permanent crosslinking through photopolymerization for
dimensional stability and enhanced mechanical strength of
hydrogels.149–151 In another way, the dimethacrylate derivatives
are used as crosslinkers to copolymerize with other monomers.
An example includes the synthesis of degradable, thermores-
ponsive PNIPAM-based hydrogels by free radical crosslinking
polymerization of NIPAM, 2-methylene-1,3-dioxepane
(MDO), and PCL-b-PEO-b-PCL dimethacrylate. These hydro-
gels degraded in alkali pH because of the degradability of
PMDO. Because of the thermoresponsiveness of PNIPAM, they
exhibited greater swelling at 4 C, below the low critical solution
temperature (LCST), compared to 37 C, above LCST. An
inverse opal of these hydrogels was fabricated PMMA micro-
spheres as sacrificial templates. The size of pores in the inverse
opal could be controlled by the size of PMMA spheres (Fig. 13).
These results suggest that PNIPAM-based scaffolds are useful
for tissue engineering applications.152 In order to improve cell
interaction, biotinylated PLA-based hydrogels were synthesized
by photo-crosslinking polymerization of a PLA-based dimetha-
crylate and a biotinylated PEG methacrylate.1533.5. Other PLA-based biomaterials for potential biomedical
applications
Glycopolymers are synthetic polymers with pendent carbohy-
drate moieties. Due to the importance of carbohydrates in
biological recognition events such as specific carbohydrate–
protein interactions and cell–cell interactions, significant efforts
have been focused on the synthesis and application of well-
controlled glycopolymers.154–156 An interesting example includes
the synthesis of polygalactose containing nanocages (named
hollow sugar balls) utilizing a combination of RAFT polymeri-
zation, shell-crosslinking, and degradation of PLA inner cores.
First, 2-(benzylsulfanylthiocarbonylsulfanyl)ethanol, a func-
tional RAFT agent, was synthesized157 and used both as an
initiator for ROP of LA and then as a mediator for RAFT
polymerization of 1,2:3,4-di-O-isopropylidene-6-O-acryloyl-a-D-
galactopyranose (AIpGP), yielding PLA-b-PAIpGP. Next, iso-
propylene protecting groups on galactopyranose rings were
removed and the resulting PLA-b-poly(6-O-acryloyl-a-D-gal-
actopyranose) (PLA-b-PAGP) ABPs self-assembled in water to
form micellar NPs consisting of PLA core surrounded with
PAGP corona. The PAGP shell was then crosslinked by free
radical polymerization of 1,6-hexanedioldiacrylate. Finally, PLA
inner core was dissolved by aminolysis with hexylamine. The
resultant hollow nanocages, confirmed by transmission electron
microscopy (TEM), could be useful for the delivery of drugs to
liver.158 Semiconducting biomaterials were composed of salt
leached PLGA and chloride-doped polypyrrole (PPy-Cl)Soft Matter, 2011, 7, 5096–5108 | 5105
Fig. 13 Schematic illustration for fabrication (a) and SEM image (b) of inverse opal of degradable, thermoresponsive PNIPAM-based hydrogels.152















































View Onlineconducting polymers. These hybrid materials were prepared via
three-steps, including (1) spin-casting of PLGA salt, (2) salt
leaching combined with PPy infusion, and (3) electrochemical
synthesis of PPy-Cl. These PPy-PLGA blends may be useful for
biomedical applications where good conductance and low
impedance are desired.1594. Summary and outlook
The hydrophobicity of PLA and its copolymers enhances the
uptake of drug-loaded NPs, resulting in their short residence
time in circulation, thus leading to a decrease in drug efficiency
in vivo. One promising approach to address the problem is to
design and synthesize ABPs that enable self-assembly toward the
formation of core/shell NPs consisting of a hydrophobic core
surrounded by hydrophilic coronas. A variety of strategies for
the synthesis of novel ABPs based on PLA and its copolymers
have been developed. Typical examples of hydrophilic polymers
include well-controlled (meth)acrylates, PEG, polypeptides,
polysaccharides, and polyurethanes. These PLA-based ABPs
have found a variety of bio-related applications; typical examples
include: self-assembled NPs for drug delivery, hydrogels for
tissue engineering, and polymer–metal NP hybrids for imaging
platforms. For drug delivery, various core/shell NPs have been
developed to load hydrophobic anticancer drugs and genes
through self-assembly and solvent evaporation. These ABPs
have been designed to have functional groups that can be utilized
for further bioconjugation to target specific cells, most often
tumors. For tissue engineering, both physical and chemical
crosslinking methods including temperature-induced sol–gel
transition, stereocomplexation, ionic interaction, and photo-
induced crosslinking polymerization have been utilized to
prepare three-dimensional crosslinked hydrogels. For imaging
platforms, metal NPs such as MNPs for MRI and QDs for
fluorescent imaging have been encapsulated in core/shell NPs.5106 | Soft Matter, 2011, 7, 5096–5108The future development of PLA-based ABPs for smart drug
delivery requires that remaining challenges to be addressed.
A challenge involves the improvement of slow and uncontrolled
release kinetics of encapsulates for currently developed
PLA-based ABPs. Another challenge is the development of
multifunctional PLA-based nanostructured materials such as
multi-responsive NPs, nanogels, and nanocapsules.
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